Delving into the Latest Updates on Banxia Xiexin Decoction with Synapse

Overview

Basic Info

Drug Type

Herbal medicine

Synonyms

SANWA Hangeshashinto Extract Fine Granules, hangeshashinto, 三和半夏瀉心湯エキス細粒

+ [3]

Target-

Mechanism-

Therapeutic Areas

Nervous System DiseasesDigestive System DisordersMouth and Tooth Diseases+ [2]

Active Indication

DiarrheaDuodenal UlcerDyspepsia+ [6]

Inactive Indication-

Originator Organization

Sanwa Shoyaku Co., Ltd.

Active Organization

Sanwa Shoyaku Co., Ltd.

Inactive Organization-

Drug Highest PhaseApproved

First Approval Date

JP (18 Jul 1986),

DiarrheaDuodenal UlcerDyspepsia+ [6]

Regulation-

Login to view timeline

Research purpose To elucidate the effect mechanism and clinical effective of Modified Banxia Xiexin Decoction in the prevention and treatment of gastric cancer. From genes related to cell differentiation, proliferation, apoptosis, tumor invasion and metastasis, genes related to immune inflammation and immune escape and other possible aspects to elucidate the effective and mechanism of Modified Banxia Xiexin Decoction's treatment on gastric cancer

Start Date01 Jan 2017

Sponsor / Collaborator

Shuguang Hospital

100 Clinical Results associated with Banxia Xiexin Decoction

Login to view more data

100 Translational Medicine associated with Banxia Xiexin Decoction

Login to view more data

100 Patents (Medical) associated with Banxia Xiexin Decoction

Login to view more data

97

Literatures (Medical) associated with Banxia Xiexin Decoction

25 Sep 2024·Journal of Agricultural and Food Chemistry

Discovery of the Chlorinated and Ammoniated Derivatives of Vanillin as Potential Insecticidal Candidates Targeting V-ATPase: Structure-Based Virtual Screening, Synthesis, and Bioassay

Article

Author: Lv, Bo ; Li, Ding ; Hu, Zhaonong ; Zhang, Xianxia ; Wang, Yu ; Wu, Wenjun

Vacuolar-type H⁺-ATPases (V-ATPases) play a crucial role in the life cycle of agricultural pests and represent a promising target for the development of novel insecticides. In this study, S18, a derivative of vanillin acquired from Specs database using a structure-based virtual screening methodology, was first identified as a V-ATPase inhibitor. It binds to subunit A of the enzyme with a K_d of 1 nM and exhibits insecticidal activity against M. separata. Subsequently, using S18 as the lead compound, a new series of vanillin derivatives were rationally designed and efficiently synthesized. and their biological activities were assessed. Among them, compound 3b-03 showed the strongest insecticidal activity against M. separata by effectively targeting the V-ATPase subunit A with K_d of 0.803 μM. Isothermal titration calorimetric measurements and docking results provided insights into its interaction with subunit A of V-ATPase, which could facilitate future research aimed at the development of novel chemical insecticides.

01 Sep 2024·3 Biotech

Banxia Xiexin Tang attenuates high glucose-induced hepatocyte injury by activating SOD2 to scavenge ROS via PGC-1α/IGFBP1

Article

Author: Huang, Xiushen ; Yang, Xu ; Wang, Qiyue ; Yue, Rensong ; Zhao, LiangBin

This study aimed to explore the protective mechanism of Banxia Xiexin Tang (BXXXT) on liver cell damage caused by high glucose (H-G) and to clarify its molecular regulatory pathways. First, the main components in BXXXT-containing serum were analyzed by high-performance liquid chromatography (HPLC) to provide basic data for subsequent experiments. Subsequently, the effect of BXXXT on high glucose (H-G)-induced hepatocyte activity was evaluated through screening of the optimal concentration of drug-containing serum. Experimental results showed that BXXXT significantly reduced the loss of cell activity caused by high glucose. Further research focuses on the regulatory effect of BXXXT on high glucose-induced hepatocyte apoptosis, especially its effect on the PGC-1α (peroxisome proliferator-activated receptor γ coactivator-1α) pathway. Experimental results showed that BXXXT reduced high-glucose-induced hepatocyte apoptosis and exerted its protective effect by upregulating the activity of the PGC-1α pathway. BXXXT significantly increased the expression level of IGFBP1 (insulin-like growth factor-binding proteins) in hepatocytes under a high-glucose environment. It cleared mitochondrial ROS (reactive oxygen species) by enhancing SOD2 (superoxide dismutase) enzyme activity and maintained the survival of hepatocytes under a high-glucose environment. Finally, the regulation of PGC-1α by BXXXT is indeed involved in the regulation of IGFBP1 expression in hepatocytes and its downstream SOD2 effector signaling. Taken together, this study provides an in-depth explanation of the protective mechanism of BXXXT on hepatocytes in a high-glucose environment, focusing on regulating the expression of the PGC-1α pathway and IGFBP1, and reducing cell damage by scavenging ROS. This provides an experimental basis for further exploring the potential of BXXXT in the treatment of diabetes-related liver injury.Supplementary InformationThe online version contains supplementary material available at 10.1007/s13205-024-04060-0.

01 Aug 2024·Chemical Biology & Drug Design

Structural modification of 2‐phenylquinoline‐4‐carboxylic acid containing SIRT3 inhibitors for the cancer differentiation therapy

Article

Author: Du, Yanmei ; Li, Fahui ; Zhang, Lei ; Fang, Chunyan ; Qin, Hongyu ; Wang, Xiaojing ; Li, Honggang ; Xu, Guangzhao ; Zhang, Lihui

AbstractInhibition of SIRT3 exhibited potency in triggering leukemic cell differentiation. In discovery of potent SIRT3 inhibitors for cancer differentiation therapy, structural modification was performed on the previously developed lead compound P6. A total of 33 compounds were designed and synthesized. In the enzyme inhibitory assay, several molecules S18, S26, S27 and T5 showed potent SIRT3 inhibitory activity with IC50 value of 0.53, 1.86, 5.06, and 2.88 μM, respectively. Moreover, the tested compounds exhibited SIRT3 inhibitory selectivity over SIRT1 and SIRT2. Compounds S27 and T5 were potent in inhibition the growth of MM1.S and RPMI‐8226 cells in the in vitro antiproliferative test. Significantly, representative compounds, especially S27 and T5, promoted differentiation of tested MM cells in the cellular morphological evaluation, accompanied by increasing the expression of differentiation antigen CD49e and human immunoglobulin light chain lambda and kappa. Additionally, molecule S18 without antiproliferative potency itself, showed significant inhibitory activity against growth factor IL‐6 induced RPMI‐8226 cell proliferation. Collectively, potent SIRT3 selective inhibitors with MM cell differentiation potency were developed for further discovery of anticancer drugs.

100 Deals associated with Banxia Xiexin Decoction

Login to view more data

R&D Status

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Diarrhea	JP	Sanwa Shoyaku Co., Ltd.	18 Jul 1986
Duodenal Ulcer	JP	Sanwa Shoyaku Co., Ltd.	18 Jul 1986
Dyspepsia	JP	Sanwa Shoyaku Co., Ltd.	18 Jul 1986
Gastroenteritis	JP	Sanwa Shoyaku Co., Ltd.	18 Jul 1986
Gastroparesis	JP	Sanwa Shoyaku Co., Ltd.	18 Jul 1986
Gastroptosis	JP	Sanwa Shoyaku Co., Ltd.	18 Jul 1986
Morning Sickness	JP	Sanwa Shoyaku Co., Ltd.	18 Jul 1986
Stomach Ulcer	JP	Sanwa Shoyaku Co., Ltd.	18 Jul 1986
Stomatitis	JP	Sanwa Shoyaku Co., Ltd.	18 Jul 1986